Last reviewed · How we verify

Placebo drug of DW-1030

Daewon Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Placebo drug of DW-1030 is a Small molecule drug developed by Daewon Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.

Placebo drugs do not have an active pharmacological mechanism; they are used as controls in clinical trials.

At a glance

Generic namePlacebo drug of DW-1030
SponsorDaewon Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebos are designed to appear identical to the active treatment but contain no active ingredients. They help researchers determine the true effect of the experimental drug by comparing outcomes against a baseline.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo drug of DW-1030

What is Placebo drug of DW-1030?

Placebo drug of DW-1030 is a Small molecule drug developed by Daewon Pharmaceutical Co., Ltd..

How does Placebo drug of DW-1030 work?

Placebo drugs do not have an active pharmacological mechanism; they are used as controls in clinical trials.

Who makes Placebo drug of DW-1030?

Placebo drug of DW-1030 is developed by Daewon Pharmaceutical Co., Ltd. (see full Daewon Pharmaceutical Co., Ltd. pipeline at /company/daewon-pharmaceutical-co-ltd).

What development phase is Placebo drug of DW-1030 in?

Placebo drug of DW-1030 is in Phase 3.

Related